原发性肠道弥漫大B细胞淋巴瘤的诊治研究进展
The Research Progress in the Diagnosis and Treatment of Primary Intestinal Diffuse Large B-cell Lymphoma——Review
陈晓君 1林素霞 1刘彦权2
作者信息
- 1. 莆田学院附属医院血液风湿科,福建莆田 351100
- 2. 广东医科大学第一临床医学院血液内科,广东东莞 523808
- 折叠
摘要
原发性肠道弥漫大B细胞淋巴瘤(PI-DLBCL)临床罕见,但近年来随着病理学与分子生物学技术逐渐成熟,其发病率、诊断率亦随之升高.由于PI-DLBCL的临床症状缺乏特异性,极易误诊、漏诊,而在临床实践中,对于PI-DLBCL的最佳治疗手段目前尚无共识.为此,本文通过检索国内外最新文献资料,旨在对PI-DLBCL的致病机制、临床表现、诊断标准、治疗及预后等方面予以系统性论述和分析,以期提高血液学与肿瘤学界对罕见PI-DLBCL的认识,并为PI-DLBCL的基础研究与临床诊疗提供借鉴与参考.
Abstract
Primary intestinal diffuse large B-cell lymphoma(PI-DLBCL)is clinically rare,but in recent years,with the gradual maturity of pathology and molecular biology technology,its incidence rate and diagnosis rate have also increased.Due to the lack of specificity of the clinical symptoms of PI-DLBCL,it is easy to misdiagnose and miss the diagnosis,and there is no consensus on the best treatment of PI-DLBCL in clinical practice.Therefore,by retrieving the latest literature at home and abroad,this review systematically discusses the pathogenesis,clinical manifestations,diagnostic criteria,treatment and prognosis of PI-DLBCL,in order to improve the understanding of rare PI-DLBCL in hematology and oncology,and provide reference for basic research and clinical diagnosis and treatment of PI-DLBCL.
关键词
弥漫大B细胞淋巴瘤/肠道肿瘤/消化系统/鉴别诊断/预后Key words
diffuse large B-cell lymphoma/intestinal tumors/differential diagnosis/prognosis引用本文复制引用
基金项目
国家自然科学基金面上项目(82073582)
广东医科大学学科建设项目(4SG23003G)
广东医科大学学科建设项目(4SG23209G)
广东医科大学科技创新专项(4SG23046G)
出版年
2024
NETL
NSTL
维普
万方数据